P3 Health Partners Inc. PIII
Medical/Nursing Services · IPO 2021 · data as of November 13, 2026
P3 Health Partners Inc. (PIII) is a healthcare company listed in the US with a market value of about $560M. In the twelve months to September 30, 2026 it had revenue of $1.6B and net income of -$51M, a net margin of -3.3%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is track record (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 59% a year, a 5-year average ROIC of -349%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 12% below the current price.
About P3 Health Partners
P3 Health Partners is listed in the US and classified in medical/nursing services, IPO year 2021. Revenue went from $145M in 2019 to $1.5B in 2025, growth of about 46.9% a year. It was profitable in 0 of the last 6 years in our data. Its share count rose by 293% over three years (dilution for shareholders).
Score: 0.8 / 5
Checks passed
- 3-year revenue growth above 10% a year
- 5-year revenue growth above 8% a year
- ROE above 15%
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $1.6B | $1.5B | $1.5B | $1.3B | $1.0B | $491M | $145M |
| Net income | -$51M | -$148M | -$136M | -$58M | -$270M | -$31M | -$42M |
| Free cash flow | -$116M | — | -$110M | -$78M | -$128M | -$28M | -$30M |
| EPS (diluted) | $-23.32 | $-45.26 | $-54.06 | $-31.50 | $-325.00 | — | — |
| Net margin | -3.3% | -10.1% | -9.0% | -4.6% | -25.7% | -6.4% | -28.8% |
| ROIC | — | -161.7% | -92.5% | -49.7% | -1090.6% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 1 analysts is $11.50, 326% above the current price; targets range from $11.50 to $11.50; the consensus rating is “Buy”; expected EPS is $-9.38 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is P3 Health Partners stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 12% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does P3 Health Partners pay a dividend?
Not currently.
Is P3 Health Partners a good stock to buy?
We do not give buy or sell advice. P3 Health Partners scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.